L Number	Hits	Search Text	DB	Time stamp
6	47	furanyl with (quinazolin or quinazolyl)	USPAT; US-PGPUB	2003/04/29 19:32
7	33	thiazol with (quinazolin or quinazolyl)	USPAT; US-PGPUB	2003/04/29 19:33

EAST

10/071,358

10/ 071,358

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Apr 11	Display formats in DGENE enhanced
NEWS 32	Apr 14	MEDLINE Reload
NEWS 33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 36	Apr 28	RDISCLOSURE now available on STN

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

10/ 071,358

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:08:40 ON 29 APR 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 19:08:49 ON 29 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0
DICTIONARY FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10071358a.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

10/ 071,358



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading 10071358.str

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR

10/ 071,358



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 19:09:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 178 TO ITERATE

100.0% PROCESSED 178 ITERATIONS 110 ANSWERS
SEARCH TIME: 00.00.01

L3 110 SEA SSS FUL L1

=> s l2 ful
FULL SEARCH INITIATED 19:09:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

L4 19 SEA SSS FUL L2

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	296.30	296.51

FILE 'CAPLUS' ENTERED AT 19:09:49 ON 29 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Apr 2003 VOL 138 ISS 18
FILE LAST UPDATED: 28 Apr 2003 (20030428/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L5 9 L3

=> s l4
L6 5 L4

=> s l5 not l6
L7 4 L5 NOT L6

=> d l6 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:555376 CAPLUS
DOCUMENT NUMBER: 137:119644
TITLE: 4-Quinazolineamine derivative combination with other antineoplastic agent for cancer treatment, and compound preparation.
INVENTOR(S): Lackey, Karen Elizabeth; Spector, Neil; Wood, Edgar Raymond, III; Xia, Wenle
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056912	A2	20020725	WO 2002-US1130	20020114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-262402P P 20010116
OTHER SOURCE(S): MARPAT 137:119644
AB A method of treating cancer is described which includes administration of a 4-quinazolineamine (prepn. included) and at least one other antineoplastic agent. Also described is a pharmaceutical combination including the 4-quinazolineamines.
IT **443883-07-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(prepn. and reaction; quinazolineamine deriv. combination with other antineoplastic agent for cancer treatment, and compd. prepn.)

RN 443883-07-6 CAPLUS

CN Acetamide, N-[[4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-thiazolyl]methyl]-2,2,2-trifluoro-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



IT **388082-82-4P 443883-12-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazolineamine deriv. combination with other antineoplastic agent for cancer treatment, and compd. prepn.)

RN 388082-82-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-, bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 388082-81-3
CMF C28 H25 Cl F N5 O3 S2



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 443883-12-3 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



IT **388082-81-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinazolineamine deriv. combination with other antineoplastic agent for cancer treatment, and compd. prepn.)
RN 388082-81-3 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:31441 CAPLUS
DOCUMENT NUMBER: 136:102396
TITLE: Preparation of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases.
INVENTOR(S): McClure, Michael Scott; Osterhout, Martin Howard;

10/ 071,358

	Roschangar, Frank; Sacchetti, Mark Joseph
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK
SOURCE:	PCT Int. Appl., 68 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002552	A1	20020110	WO 2001-US20706	20010628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1294715	A1	20030326	EP 2001-952304	20010628
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
NO 2002006196	A	20030224	NO 2002-6196	20021223

PRIORITY APPLN. INFO.:	US 2000-215508P	P	20000630
	US 2001-271845P	P	20010227
	WO 2001-US20706	W	20010628

OTHER SOURCE(S): MARPAT 136:102396

GI



I

AB Title compds. (I; R1 = Cl, Br; X = CH, N, CF; Q = thiazolylene, furylene), were prepd. Thus, 5-[4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-quinazolinyl]furan-2-carboxaldehyde 4-methylbenzenesulfonate (prepn. given), diisopropylethylamine, and 2-(methylsulfone)ethylamine were stirred 1 h in THF/IPA; he preformed imine/THF soln. was transferred to a stirred suspension of NaBH(OAc)3 in THF. After 90 min, aq. NaOH was added followed by sepn. of the aq. layer treatment of the org. layer with 4-MeC6H4SO3H to give 88% N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furyl-4-quinazolinamine ditosylate. This inhibited EGFr and ErbB2 at <0.10 .mu.M.

IT **388082-82-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases)

10/ 071,358

RN 388082-82-4 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-, bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 388082-81-3
CMF C28 H25 Cl F N5 O3 S2



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:50639 CAPLUS
DOCUMENT NUMBER: 134:100886
TITLE: Preparation of anilinoquinazolines as protein tyrosine kinase inhibitors
INVENTOR(S): Cockerill, George Stuart; Lackey, Karen Elizabeth
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001004111	A1	20010118	WO 2000-US18128	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1192151	A1	20020403	EP 2000-943348	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003504363	T2	20030204	JP 2001-509721	20000630

PRIORITY APPLN. INFO.:	GB 1999-16213	A	19990709
	GB 1999-16218	A	19990709
	WO 2000-US18128	W	20000630

OTHER SOURCE(S): MARPAT 134:100886
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; X = CR1 and Y = N; or X = N and Y = CR1; X = CR1 and Y = CR2; X = CR2 and Y = CR1; R1 = Ar(CH2)pZCH2CH2SO2R5 (wherein Ar = (un)substituted Ph, furan, thiophene, etc.; Z = O, S, NH, NR6; p = 1-4; R5 = alkyl substituted by 5-10 membered heterocyclic group, 3-10 membered carbocyclic group, etc.; R6 = alkyl, alkoxyalkyl, hydroxyalkyl, etc.); R2 = H, halo, OH, etc.; R3 = pyridylmethoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy; R4 = H, halo, alkyl, etc.; with the proviso that when p = 1 and Z = NH, R5 cannot represent Me] which exhibit protein tyrosine kinase inhibition, in particular erbB family kinase inhibition, and useful in treating cancer and psoriasis, were prepd. E.g., a multi-step synthesis of the anilinoquinazoline II was given. Biol. data (erbB-2, erbB-4, EGFr, and cell proliferation inhibition) for the compds. I were presented.

IT **319917-42-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anilinoquinazolines as protein tyrosine kinase inhibitors)

RN 319917-42-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[2-[[2-(methylsulfonyl)ethyl]amino]ethyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



IT **320337-50-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of anilinoquinazolines as protein tyrosine kinase inhibitors)
RN 320337-50-6 CAPLUS
CN 2-Thiazoleacetic acid, 4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



IT **307327-30-6P 320337-33-5P 320337-34-6P**
320337-35-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of anilinoquinazolines as protein tyrosine kinase inhibitors)
RN 307327-30-6 CAPLUS
CN 2-Thiazolecarboxaldehyde, 4-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 320337-33-5 CAPLUS
CN 2-Thiazoleacetonitrile, 4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 320337-34-6 CAPLUS
CN 4-Quinazolinamine, 6-[2-(2-aminoethyl)-4-thiazolyl]-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 320337-35-7 CAPLUS
CN Acetamide, N-[2-[4-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-thiazolyl]ethyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:854415 CAPLUS
DOCUMENT NUMBER: 133:362769
TITLE: Preparation of 6-(thiomorpholinomethylfuranyl)-4-quinazolinamines as protein tyrosine kinase inhibitors
INVENTOR(S): Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK

10/ 071,358

SOURCE: Brit. UK Pat. Appl., 151 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2345486	A1	20000712	GB 1999-29973	19991217

PRIORITY APPLN. INFO.: GB 1999-518 A 19990111
GB 1999-15510 A 19990703

OTHER SOURCE(S): MARPAT 133:362769
GI



I



II

AB The title compds. (I) [wherein X = N or CH; V and Y = independently CR1, CR2, or N; and V .noteq. Y; R1 = Q(CH2)qAr; m = 1 or 2; p = 1 or 2; q = 1-4; Ar = (un)substituted Ph, furanyl, thiophenyl, pyrrolyl, or thiazolyl; R2 = H, halo, OH, alkyl(amino) alkoxy, or dialkylamino; U = (un)substituted Ph, pyridyl, (benz)imidazolyl, (iso)indolyl, (iso)indolinyl, indazolyl, or benzotriazolyl] were prepd. as protein tyrosine kinase inhibitors for the treatment of cancer and other disorders mediated by aberrant protein tyrosine kinase activity. For example, II.bul.2HCl was formed in a multi-step sequence involving (1) reaction of 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan with (4-benzyloxyphenyl)(6-bromoquinazolin-4-yl)amine using Pd(PPh3)2Cl2 in dioxane, (2) conversion of the cyclic acetal to the aldehyde with HCl in THF, (3) addn. of thiomorpholine-S-oxide in CH2Cl2 and conversion to the HCl salt. I inhibited EGFR and c-erbB-2 tyrosine kinase with IC50 < 0.10 .mu.M and suppressed cell proliferation against a range of tumor cell lines.

IT **307328-15-0P**, (4-Benzyloxyphenyl)-[6-[2-((1-oxothiomorpholin-4-yl)methyl)thiazol-4-yl]quinazolin-4-yl]amine dihydrochloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addn. of thiomorpholine (oxides))

10/ 071,358

RN 307328-15-0 CAPLUS
CN 4-Quinazolinamine, 6-[2-[(1-oxido-4-thiomorpholinyl)methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT **307327-30-6P**, 4-[4-[(4-Benzyloxyphenyl)amino]quinazolin-6-yl]thiazole-2-carbaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of thiomorpholinomethylfuranyl quinazolinamine and pyrido[3,4-d]pyrimidinamine anticancer agents by amination of (haloheterocyclyl)furancarboxaldehydes with anilines followed by addn. of thiomorpholine (oxides))
RN 307327-30-6 CAPLUS
CN 2-Thiazolecarboxaldehyde, 4-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:451297 CAPLUS
DOCUMENT NUMBER: 131:102288
TITLE: Bicyclic heteroaromatic compounds [quinazolinamines, pyridopyrimidines, and analogs] useful as protein tyrosine kinase inhibitors
INVENTOR(S): Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane
PATENT ASSIGNEE(S): Glaxo Group Limited, UK

10/ 071,358

SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935146	A1	19990715	WO 1999-EP48	19990108
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2317589	AA	19990715	CA 1999-2317589	19990108
AU 9922783	A1	19990726	AU 1999-22783	19990108
AU 749549	B2	20020627		
BR 9906904	A	20001017	BR 1999-6904	19990108
EP 1047694	A1	20001102	EP 1999-902522	19990108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200000411	A	20011217	EE 2000-411	19990108
JP 2002500225	T2	20020108	JP 2000-527545	19990108
JP 2002326990	A2	20021115	JP 2002-92102	19990108
ZA 9900172	A	20000711	ZA 1999-172	19990111
TW 477788	B	20020301	TW 1999-88100388	19990112
NO 2000003561	A	20000911	NO 2000-3561	20000711
BG 104668	A	20010430	BG 2000-104668	20000807
US 2002147205	A1	20021010	US 2002-71358	20020208

PRIORITY APPLN. INFO.:
GB 1998-569 A 19980112
JP 2000-527545 A3 19990108
WO 1999-EP48 W 19990108
US 2000-582746 A1 20000630

OTHER SOURCE(S): MARPAT 131:102288
GI



I



II

AB Title compds. I and their salts and solvates are disclosed [wherein X = N

or CH; Y = CR1 and V = N; or Y = N and V = CR1; or Y = CR1 and V = CR2; or Y = CR2 and V = CR1; R1 = MeSO2CH2CH2NHCH2-Ar-, wherein Ar = (un)substituted Ph, furan, thiophene, pyrrole, or thiazole; R2 = H, halo, OH, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, or di[C1-4 alkyl]amino; U = Ph, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by R3 and optionally by R4; R3 = (halo)benzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and (halo)benzyloxy, PhSO2, (trihalomethyl)benzyl, (trihalomethyl)benzyloxy, (R5)n-substituted phthalimido; R4 = OH, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, (di)(alkyl)amino, C1-4 alkylthio, etc.; R5 = halo, C1-4 alkyl, C1-4 alkoxy; n = 0-3]. Also disclosed are methods for their prepn., pharmaceutical compns. contg. them, and their use in medicine. The compds. are inhibitors of protein tyrosine kinases, and as such are useful in the treatment of cancer, psoriasis, and rheumatoid arthritis. Over 40 title compds. and numerous intermediates were prepd. For example, 4,6-dichloropyrido[3,4-d]pyrimidine was condensed with 4-[(4-fluorobenzyl)oxy]aniline at the 4-chloro position, followed by Pd-catalyzed coupling with 5-(1,3-dioxolan-2-yl)-2-(tributylstannyl)furan at the 6-chloro position, hydrolysis of the dioxolane protecting group to give an aldehyde, reductive amination of the latter with MeSCH2CH2NH2, and finally S-oxidn. with Oxone .RTM. and acidification, to give title salt II.2HCl. In a methylene blue growth inhibition assay against 5 tumor cell lines, II.2HCl had an IC50 of < 5 .mu.M against 4 of them, and an IC50 of 25-50 .mu.M against the 5th.

IT **231277-70-6P 231277-75-1P 231277-76-2P**
231277-77-3P 231277-78-4P 231277-87-5P
231277-88-6P 231278-07-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of quinazolinamines and analogs as protein tyrosine kinase inhibitors)

RN 231277-70-6 CAPLUS

CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 231277-75-1 CAPLUS

CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX

NAME)



RN 231277-76-2 CAPLUS
CN 4-Quinazolinamine, N-[4-[(3-bromophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 231277-77-3 CAPLUS
CN 4-Quinazolinamine, N-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 231277-78-4 CAPLUS
CN 4-Quinazolinamine, N-[3-fluoro-4-(phenylmethoxy)phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 231277-87-5 CAPLUS
CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 231277-88-6 CAPLUS
CN 4-Quinazolinamine, N-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]- (9CI) (CA INDEX NAME)



RN 231278-07-2 CAPLUS
CN 4-Quinazolinamine, 6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 19:08:40 ON 29 APR 2003)

FILE 'REGISTRY' ENTERED AT 19:08:49 ON 29 APR 2003
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 110 S L1 FUL
L4 19 S L2 FUL

FILE 'CAPLUS' ENTERED AT 19:09:49 ON 29 APR 2003
L5 9 S L3
L6 5 S L4
L7 4 S L5 NOT L6

=> d l7 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:668812 CAPLUS
TITLE: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
AUTHOR(S): Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.
CORPORATE SOURCE: GlaxoSmithKline, Department of Discovery Medicine, Research Triangle Park, North Carolina, NC, 27709-3398, USA
SOURCE: Oncogene (2002), 21(41), 6255-6263
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, resp. Complete inhibition of activated AKT in erbB2 overexpressing cells

correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.

IT **231277-92-2**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GW572016 antitumor activity: dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:117136 CAPLUS

DOCUMENT NUMBER: 137:125053

TITLE: Use of lithium N,O-dimethylhydroxylamide as an efficient in situ protecting agent for aromatic aldehydes

AUTHOR(S): Roschangar, Frank; Brown, Jennifer C.; Cooley, Bobby E.; Sharp, Matthew J.; Matsuoka, Richard T.

CORPORATE SOURCE: GlaxoSmithKline, Chemical Development--Synthetic Chemistry, Research Triangle Park, NC, 27709, USA

SOURCE: Tetrahedron (2002), 58(9), 1657-1666
CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:125053

AB Lithium N,O-dimethylhydroxylamide was effectively used as an alternative

in situ protecting agent with low ortho-directing properties for aryl and heteroaryl aldehydes RCHO (R = Ph, 2,5-F(Br)C6H3, 2-furyl). The procedure was successfully applied to two practical multi-step one-pot syntheses of developmental drug candidate intermediates. Aldehyde protecting and ortho-directing properties of other lithium dialkylamides, such as diethylamide, morpholide, etc., were also evaluated.

IT **231278-84-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of substituted (quinazolinyl)furaldehyde by Suzuki coupling of iodoquinazoline deriv. with (formyl)furylboronic acid, prepd. from lithium alkylamide protected furaldehyde)

RN 231278-84-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:669418 CAPLUS
DOCUMENT NUMBER: 136:19979
TITLE: A practical one-pot synthesis of 5-aryl-2-furaldehydes
AUTHOR(S): McClure, Michael S.; Roschangar, Frank; Hodson, Stephen J.; Millar, Alan; Osterhout, Martin H.
CORPORATE SOURCE: Chemical Development - Synthetic Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
SOURCE: Synthesis (2001), (11), 1681-1685
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:19979

AB A useful 1-pot synthesis of 5-aryl-2-furaldehydes via Pd-mediated Suzuki coupling of aryl halides with in situ generated 5-(diethoxymethyl)-2-furylboronic acid is described. The procedure has general applicability, delivers high yields, and is amenable to scale-up.

IT **231278-84-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arylfuraldehydes by Suzuki coupling of aryl halides with

furylboronic acids)
RN 231278-84-5 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:71133 CAPLUS
DOCUMENT NUMBER: 128:140716
TITLE: Preparation of azolylquinazolines and related compounds as protein tyrosine kinase inhibitors.
INVENTOR(S): Cockerill, George Stuart; Carter, Malcolm Clive; Guntrip, Stephen Barry; Smith, Kathryn Jane
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Cockerill, George Stuart; Carter, Malcolm Clive; Guntrip, Stephen Barry; Smith, Kathryn Jane
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9802434	A1	19980122	WO 1997-EP3672	19970711
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9706147	A	19990111	ZA 1997-6147	19970710
AU 9737668	A1	19980209	AU 1997-37668	19970711
EP 912559	A1	19990506	EP 1997-934458	19970711
EP 912559	B1	20021106		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2000514806	T2	20001107	JP 1998-505596		19970711
AT 227283	E	20021115	AT 1997-934458		19970711
US 6391874	B1	20020521	US 1998-214267		19981231
US 2002147214	A1	20021010	US 2002-62647		20020131

PRIORITY APPLN. INFO.:

GB 1996-14755	A	19960713
GB 1996-25458	A	19961207
WO 1997-EP3672	W	19970711
US 1998-214267	A1	19981231

OTHER SOURCE(S): MARPAT 128:140716

GI



I

AB Title compds. [I; U = substituted Ph, mono- or bicyclic 5-10 membered (hetero)cyclyl; X = N, CH; Y = W(CH2), (CH2)W, W; W = O, S(O)m, NRa; Ra = H, alkyl; m = 0-2; R1 = (substituted) Ph, 5- or 6-membered heterocyclyl contg. 1-4 heteroatoms selected from N, O, S(O)m; with the provision that the ring does not contain two adjacent O or S(O)m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring; R3 = H, amino, halo, OH, NO2, CO2H, CHO, cyano, CF3, OCF3, carbamoyl, alkoxycarbonyl, Ph, PhO, pyridonyl, pyrrolidinyl, imidazolyl, dioxolanyl, arylsulfonyl, alkylsulfonyl, alkylcarbamoylalkyl, piperidinoalkoxy, thiomorpholino, etc.; 2 adjacent R3 = methylenedioxy, ethylenedioxy; p = 0-3], were prepd. Thus, (S)-1-[5-[4-(1-benzyl-1H-indazol-5-ylamino)quinazolin-6-yl]furan-2-ylmethyl]pyrrolidine-2-carboxylic acid amide dihydrochloride (prepn. given) inhibited BT474 human breast cancer cell proliferation with IC50 = 2 nM.

IT **202196-33-6P 202196-42-7P 202196-46-1P**
202196-47-2P 202196-48-3P 202196-49-4P
202196-50-7P 202196-51-8P 202196-52-9P
202196-85-8P 202196-86-9P 202196-87-0P
202196-88-1P 202196-89-2P 202196-90-5P
202196-91-6P 202197-80-6P 202197-81-7P
202197-82-8P 202198-08-1P 202198-09-2P
202198-10-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)

RN 202196-33-6 CAPLUS

CN 4-Quinazolinamine, 6-(2-furanyl)-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 202196-42-7 CAPLUS
CN 4-Quinazolinamine, 6-[5-(1,3-dioxolan-2-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 202196-46-1 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-47-2 CAPLUS
CN 4-Quinazolinamine, 6-[5-[(4-methyl-1-piperazinyl)methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 202196-48-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202196-49-4 CAPLUS
CN 1,2-Propanediamine, N1,N1-dimethyl-N2-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)



RN 202196-50-7 CAPLUS
CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]- (9CI) (CA INDEX NAME)



RN 202196-51-8 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[(3-pyridinylamino)methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 202196-52-9 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]- (9CI) (CA INDEX NAME)



RN 202196-85-8 CAPLUS
CN 4-Quinazolinamine, 6-[5-[[methyl[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 202196-86-9 CAPLUS
CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 202196-87-0 CAPLUS
CN Ethanesulfonamide, 2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 202196-88-1 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 202196-89-2 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-90-5 CAPLUS
CN 2-Furancarboxamide, N-[2-(methylsulfonyl)ethyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 202196-91-6 CAPLUS
CN Ethanesulfonamide, N-methyl-2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 202197-80-6 CAPLUS
CN 2-Furancarboxaldehyde, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202197-81-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 202197-82-8 CAPLUS
CN 4-Quinazolinamine, N-[4-(phenylmethoxy)phenyl]-6-[5-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]-2-furanyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-08-1 CAPLUS
CN Methanesulfonamide, N-[2-[[[5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-2-furanyl]methyl]amino]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 202198-09-2 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 202198-10-5 CAPLUS
CN 2-Furancarboxamide, N-[2-(methylsulfonyl)ethyl]-5-[4-[[4-(phenylmethoxy)phenyl]amino]-6-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **202197-65-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azolylquinazolines and related compds. as protein tyrosine kinase inhibitors)
RN 202197-65-7 CAPLUS
CN 4-Quinazolinamine, 6-[5-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)-2-furanyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

10/ 071,358



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 19:08:40 ON 29 APR 2003)

FILE 'REGISTRY' ENTERED AT 19:08:49 ON 29 APR 2003
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 110 S L1 FUL
L4 19 S L2 FUL

FILE 'CAPLUS' ENTERED AT 19:09:49 ON 29 APR 2003
L5 9 S L3
L6 5 S L4
L7 4 S L5 NOT L6

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	42.08	338.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.86	-5.86

STN INTERNATIONAL LOGOFF AT 19:11:44 ON 29 APR 2003